Sanofi in­vests in the fu­ture of mR­NA with plan to pump bil­lions of dol­lars in­to next-gen cell ther­a­py busi­ness

With Mod­er­na and Pfiz­er/BioN­Tech paving the road for mR­NA ther­a­peu­tics, a gold rush is un­der­way across bio­phar­ma to take that promis­ing ba­ton and run with it in­to new dis­ease ar­eas. Now, Sanofi is en­gi­neer­ing an am­bi­tious — and ex­pen­sive —plan to re­tool its R&D ap­proach around mR­NA vac­cines, and it’s lean­ing on a ma­jor re­search pact to help get it there.

Sanofi will in­vest up to $477 mil­lion per year to build out its “end-to-end” in­ter­nal ca­pa­bil­i­ties in mR­NA, the cell ther­a­py tech­nol­o­gy un­der­pin­ning Mod­er­na and Pfiz­er/BioN­Tech’s Covid-19 vac­cines with red-hot po­ten­tial in oth­er dis­eases, the French drug­mak­er said Tues­day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER